Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV-Reference-Cited by-同舟云学术

Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV

Published:2017-07 Issue:2 Volume:2 Page:238146831771644
ISSN:2381-4683
Container-title:MDM Policy & Practice
language:en
Short-container-title:MDM Policy & Practice

Author:

Joyce Vilija R.¹²³⁴⁵,Sun Huiying¹²³⁴⁵,Barnett Paul G.¹²³⁴⁵,Bansback Nick¹²³⁴⁵,Griffin Susan C.¹²³⁴⁵,Bayoumi Ahmed M.¹²³⁴⁵,Anis Aslam H.¹²³⁴⁵,Sculpher Mark¹²³⁴⁵,Cameron William¹²³⁴⁵,Brown Sheldon T.¹²³⁴⁵,Holodniy Mark¹²³⁴⁵,Owens Douglas K.¹²³⁴⁵

Affiliation:

1. VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR&D Health Economics Resource Center, Menlo Park, California (VRJ, PGB)

2. Centre for Health Evaluation and Outcome Sciences, St. Paul’s Hospital, Vancouver, British Columbia, Canada (HS, NB, AHA)

3. Canadian HIV Trials Network, Vancouver, British Columbia, Canada (HS)

4. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada (NB, AHA)

5. Centre for Health Economics, University of York, York, UK (SCG, MS)

Publisher

SAGE Publications

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.1177/2381468317716440

Reference40 articles.

1. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less